PCT Webinar hosted by Ataxia UK
Last October, we hosted a webinar entitled “Involving patients and patients groups in clinical research”. The webinar was a precursor to the ‘Partnerships in Clinical trials’ conference which was hosted in Vienna in November.
The webinar we hosted was recorded and can be re-watched here.
Retrotope announces Phase I/II Clinical Trial Results of RT001 in Treatment of Friedreich’s ataxia
This trial was announced by Retrotope at the International Ataxia Research Conference organised last year in Windsor. The company run a randomised double blind Phase I trial using a modified fatty acid (RT0001) in US with 18 participants with FA, and testing two doses for one month. The first set of results showed that the drug was safe and well tolerated, and the maximum tolerated dose was identified. Some signs of drug effect could be seen and therefore the decision to extend this study to another 6 months to refine the dose with a more relaxed diet (including fatty acids) was made. If you wish to read more about this trial, please have a look at the press release here.